EP2389189A4 - Method for the prevention and treatment of diastolic dysfunction employing an apolipoproteina1 (apoa1) mimetic peptide/phospholipid complex - Google Patents

Method for the prevention and treatment of diastolic dysfunction employing an apolipoproteina1 (apoa1) mimetic peptide/phospholipid complex

Info

Publication number
EP2389189A4
EP2389189A4 EP10733186A EP10733186A EP2389189A4 EP 2389189 A4 EP2389189 A4 EP 2389189A4 EP 10733186 A EP10733186 A EP 10733186A EP 10733186 A EP10733186 A EP 10733186A EP 2389189 A4 EP2389189 A4 EP 2389189A4
Authority
EP
European Patent Office
Prior art keywords
apoa1
prevention
treatment
diastolic dysfunction
mimetic peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10733186A
Other languages
German (de)
French (fr)
Other versions
EP2389189A1 (en
Inventor
Jean-Claude Tardif
David Busseuil
Eric Rheaume
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut de Cardiologie de Montreal
Original Assignee
Institut de Cardiologie de Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut de Cardiologie de Montreal filed Critical Institut de Cardiologie de Montreal
Publication of EP2389189A1 publication Critical patent/EP2389189A1/en
Publication of EP2389189A4 publication Critical patent/EP2389189A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP10733186A 2009-01-23 2010-01-25 Method for the prevention and treatment of diastolic dysfunction employing an apolipoproteina1 (apoa1) mimetic peptide/phospholipid complex Withdrawn EP2389189A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20205109P 2009-01-23 2009-01-23
US20219109P 2009-02-05 2009-02-05
PCT/CA2010/000108 WO2010083611A1 (en) 2009-01-23 2010-01-25 Method for the prevention and treatment of diastolic dysfunction employing an apolipoproteina1 (apoa1) mimetic peptide/phospholipid complex

Publications (2)

Publication Number Publication Date
EP2389189A1 EP2389189A1 (en) 2011-11-30
EP2389189A4 true EP2389189A4 (en) 2012-12-19

Family

ID=42355467

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10733186A Withdrawn EP2389189A4 (en) 2009-01-23 2010-01-25 Method for the prevention and treatment of diastolic dysfunction employing an apolipoproteina1 (apoa1) mimetic peptide/phospholipid complex

Country Status (3)

Country Link
EP (1) EP2389189A4 (en)
CA (1) CA2788223A1 (en)
WO (1) WO2010083611A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2982157A1 (en) 2009-02-16 2010-08-19 Cerenis Therapeutics Holding Sa Apolipoprotein a-i mimics
EP2598158A4 (en) * 2010-07-28 2014-03-12 Inst Cardiologie Montreal Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction comprising an apolipoprotein peptide/phospholipid complex
CA2807448A1 (en) 2010-08-30 2012-03-08 F. Hoffmann-La Roche Ag Tetranectin-apolipoprotein a-i, lipid particles containing it and its use
KR20140054115A (en) 2011-08-25 2014-05-08 에프. 호프만-라 로슈 아게 Shortened tetranectin-apolipoprotein a-i fusion protein, a lipid particle containing it, and uses thereof
US9402975B2 (en) 2011-08-31 2016-08-02 Becton, Dickinson And Company Systems and methods to increase rigidity and snag-resistance of catheter tip

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
WO2000059855A1 (en) 1999-04-01 2000-10-12 Esperion Therapeutics, Inc. Ether compounds, compositions, and uses thereof
EP2537526A1 (en) * 2006-06-01 2012-12-26 Institut de Cardiologie de Montréal Method and compound for the treatment of valvular stenosis

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BEYERBACHT H P ET AL: "Aortic valve replacement in patients with aortic valve stenosis improves myocardial metabolism and diastolic function.", June 2001, RADIOLOGY JUN 2001 LNKD- PUBMED:11376247, VOL. 219, NR. 3, PAGE(S) 637 - 643, ISSN: 0033-8419, XP002686474 *
BUSSEUIL D ET AL: "Regression of aortic valve stenosis by ApoA-I mimetic peptide infusions in rabbits.", June 2008, BRITISH JOURNAL OF PHARMACOLOGY JUN 2008 LNKD- PUBMED:18414386, VOL. 154, NR. 4, PAGE(S) 765 - 773, ISSN: 0007-1188, XP002686476 *
BUSSEUIL DAVID ET AL: "[A new type of medical treatment could lead to regression of aortic valve stenosis].", August 2008, MÉDECINE SCIENCES : M/S 2008 AUG-SEP LNKD- PUBMED:18789203, VOL. 24, NR. 8-9, PAGE(S) 675 - 676, ISSN: 0767-0974, XP002686475 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; July 2000 (2000-07-01), RISTIC-ANDJELKOV A ET AL: "[Echocardiographic evaluation of left ventricular diastolic function in patients with aortic valve stenosis].", XP002686473, Database accession no. NLM11521465 *
MANDINOV L ET AL: "Diastolic heart failure", CARDIOVASCULAR RESEARCH, OXFORD UNIVERSITY PRESS, GB, vol. 45, 1 January 2000 (2000-01-01), pages 813 - 825, XP002903841, ISSN: 0008-6363, DOI: 10.1016/S0008-6363(99)00399-5 *
MARCHESI ET AL: "Apolipoprotein A-IMilano/POPC complex attenuates post-ischemic ventricular dysfunction in the isolated rabbit heart", ATHEROSCLEROSIS, ELSEVIER IRELAND LTD, IE, vol. 197, no. 2, 22 October 2007 (2007-10-22), pages 572 - 578, XP022559364, ISSN: 0021-9150, DOI: 10.1016/J.ATHEROSCLEROSIS.2007.08.028 *
OLCAY AKSOY ET AL: "Do Bisphosphonates Slow the Progression of Aortic Stenosis?", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, NEW YORK, NY, US, vol. 59, no. 16, 2 January 2012 (2012-01-02), pages 1452 - 1459, XP028406141, ISSN: 0735-1097, [retrieved on 20120303], DOI: 10.1016/J.JACC.2012.01.024 *
See also references of WO2010083611A1 *

Also Published As

Publication number Publication date
CA2788223A1 (en) 2010-07-29
EP2389189A1 (en) 2011-11-30
WO2010083611A1 (en) 2010-07-29

Similar Documents

Publication Publication Date Title
HK1215182A1 (en) Herapeutic agents comprising elastin-like peptides
HK1208237A1 (en) Methods for the treatment of gout
HK1217293A1 (en) Methods for the prevention or treatment of heart failure
ZA201204625B (en) Analogues for the treatment or prevention of flavivirus infections
GB2464906B (en) Cryogenic treatment of gas
IL218116A (en) Modified vasoactive intestinal peptides comprising elastin-like peptides
IL217503A0 (en) Benzimidazole analogues for the treatment or prevention of flavivirus infections
EP2068768A4 (en) Method and system for improving diastolic function of the heart
EP2097012A4 (en) Devices and methods for the treatment of heart failure
EP2032131A4 (en) Method of treatment
EP2352515A4 (en) Method for the treatment of hemophilia
EP1995254A4 (en) Method of producing peptide
HK1149322A1 (en) Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
HK1155075A1 (en) Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
GB0610746D0 (en) Method of treatment
HK1167148A1 (en) Method for the preparation of cyclopeptides
EP2717902A4 (en) Use of modified vasoactive intestinal peptides in the treatment of hypertension
EP1996609A4 (en) Method of preparing glycopeptides
EP2389189A4 (en) Method for the prevention and treatment of diastolic dysfunction employing an apolipoproteina1 (apoa1) mimetic peptide/phospholipid complex
HK1134911A1 (en) Medicament for the treatment of endometriosis
EP2411042A4 (en) Tissue kallikrein for the treatment of pancreatic -cell dysfunction
EP2270141A4 (en) Partial peptide of lacritin
EP2262594A4 (en) Cleaning bullet and method of operating the same
ZA201200420B (en) Method for the purification of protein complexes
GB0724953D0 (en) Methods of peptide modification

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110823

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/00 20060101ALI20121107BHEP

Ipc: A61K 38/17 20060101AFI20121107BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20121120

17Q First examination report despatched

Effective date: 20131025

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20141030

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150310